Esperion Appoints Benjamin O. Looker as General Counsel
January 04 2022 - 8:00AM
Esperion (NASDAQ: ESPR), today announced the appointment of
Benjamin O. Looker as general counsel as of January 1, 2022. Mr.
Looker will serve as a member of the Esperion executive leadership
team effective immediately. In his role, Mr. Looker will lead the
company’s legal, compliance and ethics operations.
“Mr. Looker is a highly experienced legal executive with broad
pharmaceutical industry experience, and proven skill supporting
clinical and commercial stage companies, and I welcome him to
Esperion,” said Sheldon Koenig, President and Chief Executive
Officer of Esperion. “Mr. Looker’s guidance and expertise will be
especially valuable during this pivotal time as we progress towards
the completion of our unprecedented CLEAR Outcomes trial and
continue exploration and development of our pre-clinical
pipeline.”
“I am thrilled to join the team at Esperion, particularly at
such an exciting time as we anticipate the completion of the
cardiovascular outcomes trial and determine future steps for the
company’s early stage pipeline that has potential to impact
millions of patients,” said Mr. Looker.
Mr. Looker began his legal career as a corporate lawyer at
Goodwin Procter LLP and joins Esperion most recently from Trillium
Therapeutics, where he served on the executive team as the
company’s first general counsel, managing all of the company’s
legal matters, including corporate governance and SEC compliance,
risk management and intellectual property asset protection, until
the company’s acquisition by Pfizer Inc. in November 2021. Prior to
Trillium Therapeutics, he served as Vice President, Head of U.S.
Legal and Global Business Operations for MorphoSys US Inc., a
commercial-stage biopharmaceutical company where he provided
guidance on multiple business initiatives, including sales and
marketing activities, business development, corporate structure,
the enforcement environment and risk mitigation strategies. Prior
to MorphoSys, Mr. Looker held legal roles of increasing
responsibility at EMD Serono, Inc., a U.S. subsidiary of Merck KGaA
Darmstadt, Germany. Mr. Looker received his B.S. degree in finance
and management information systems from Boston College and his J.D.
from Boston College Law School.
Esperion Therapeutics
Esperion works hard to make our medicines easy to get, easy to
take and easy to have. We discover, develop and commercialize
innovative medicines and combinations to lower cholesterol,
especially for patients whose needs aren’t being met by the status
quo. Our entrepreneurial team of industry leaders is inclusive,
passionate and resourceful. We are singularly focused on managing
cholesterol so you can improve your health easily. Esperion
commercializes NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic
acid and ezetimibe) Tablets and is the leader in the development of
convenient oral, once-daily non-statin LDL-cholesterol lowering
drugs for patients with high levels of bad cholesterol. For more
information, please visit www.esperion.com and follow us on Twitter
at www.twitter.com/EsperionInc.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding commercialization
plans. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties that could cause Esperion's actual results
to differ significantly from those projected, including, without
limitation, the impact of COVID-19 on our business, clinical
activities, supply chain, commercial development and launch plans,
and the risks detailed in Esperion’s filings with the Securities
and Exchange Commission. Any forward-looking statements contained
in this press release speak only as of the date hereof, and
Esperion disclaims any obligation or undertaking to update or
revise any forward-looking statements contained in this press
release, other than to the extent required by law.
Contact:Ben Churchbchurch@esperion.com
734-864-6774
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024